Background: Predictive biomarkers for immunotherapy in lung cancer are intensively investigated; however, correlations between PD-L1/PD-1 expressions and clinical features or histopathological
Background PD-1 inhibitors have been approved for the first-line treatment of patients with advanced gastric cancer, gastroesophageal junction cancer or esophageal adenocarcinoma. However, the results
Diverse combination therapies are being investigated to overcome the limitations of immune checkpoint inhibitors. However, determining the optimal combination therapy remains a challenge. Herein, we d
